At a glance
- Originator Eli Lilly
- Class Neuroprotectants; Nootropics; Small molecules; Tetrazoles
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neuroprotection
Most Recent Events
- 18 Dec 1996 No-Development-Reported for Neuroprotection in United Kingdom (Unknown route)
- 18 Dec 1996 No-Development-Reported for Neuroprotection in USA (Unknown route)